Esperion Therapeutics Reports 23.3% Revenue Growth in Q1 2026, Net Loss Improves

Esperion Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $80.1 million, a 23.3% increase from $65.0 million in the same period of 2025. This growth was driven by a rise in product sales, which reached $43.4 million, up from $34.9 million year-over-year, and collaboration revenue that increased to $36.7 million from $30.1 million. Despite this revenue growth, the company reported a net loss of $25.2 million for the quarter, an improvement from the $40.5 million loss recorded in the first quarter of 2025.

The company's operating expenses for the quarter were $86.7 million, slightly down from $87.1 million in the previous year. Notably, research and development expenses decreased to $9.0 million from $12.6 million, reflecting a strategic shift in resource allocation. Selling, general, and administrative expenses remained relatively stable at $43.1 million compared to $43.0 million in the prior year. The reduction in losses was attributed to improved operational efficiencies and increased revenue from product sales.

In terms of strategic developments, Esperion completed the acquisition of Corstasis Therapeutics on April 2, 2026, for an upfront payment of $75 million, with potential milestone payments of up to $180 million. This acquisition is expected to enhance Esperion's cardiovascular portfolio with the addition of Enbumyst, an FDA-approved nasal spray for treating edema associated with heart failure. Furthermore, the company is in the process of merging with Essence Parent Inc., which is anticipated to close in the third quarter of 2026, subject to stockholder approval.

Operationally, Esperion's cash and cash equivalents stood at $156.2 million as of March 31, 2026, a decrease from $167.9 million at the end of 2025. The company reported a net cash used in operating activities of $27.7 million for the quarter, compared to $22.6 million in the same period last year. The increase in cash outflow was primarily due to ongoing commercialization efforts for its products and research and development activities. The company continues to rely on collaborations and strategic partnerships to fund its operations and advance its product pipeline.

Looking ahead, Esperion anticipates continued operating losses as it invests in the commercialization of NEXLETOL and NEXLIZET, as well as the integration of Corstasis and the launch of Enbumyst. The company expects that its current cash resources, along with future revenues from product sales and collaboration agreements, will be sufficient to fund operations for the foreseeable future. However, management acknowledges the need for additional financing to support ongoing activities and achieve long-term profitability.